Boachie Ahmed, Goldfield Gary S, Spettigue Wendy
Department of Psychiatry, Children's Hospital of Eastern Ontario, Ottawa, Canada.
Int J Eat Disord. 2003 Jan;33(1):98-103. doi: 10.1002/eat.10115.
A recent case report suggested that olanzapine resulted in improved weight gain and maintenance, as well as decreased anxiety and agitation, for two hospitalized inpatients with anorexia nervosa (AN). However, a subsequent larger case study did not show a relationship between the use of olanzapine and rate of weight gain among a primarily adult population. The aim of this case report was to clinically examine the therapeutic benefit and tolerability of olanzapine as an adjunctive treatment for four children with AN in a pediatric inpatient setting.
Olanzapine use was associated with considerable weight gain and maintenance, with an average rate of weight gain during hospitalization of 0.99 kg per week. In addition to weight gain, olanzapine was associated with a clinically notable decrease in levels of agitation and premeal anxiety and almost immediate improvement in sleep, general functioning, and overall compliance with treatment. Olanzapine was also well tolerated in these young patients.
These case report findings warrant more controlled research, including randomized controlled studies, to better determine the therapeutic benefits and safety of olanzapine use in children with AN.
最近一份病例报告表明,奥氮平使两名神经性厌食症(AN)住院患者的体重增加并得以维持,同时焦虑和激越症状减轻。然而,随后一项规模更大的病例研究并未显示在以成年人为主的人群中使用奥氮平与体重增加速率之间存在关联。本病例报告的目的是在儿科住院环境中临床检验奥氮平作为四名AN患儿辅助治疗的疗效和耐受性。
使用奥氮平与显著的体重增加和维持有关,住院期间体重增加平均速率为每周0.99千克。除体重增加外,奥氮平还使激越和餐前焦虑水平在临床上显著降低,睡眠、总体功能及治疗总体依从性几乎立即得到改善。奥氮平在这些年轻患者中耐受性也良好。
这些病例报告结果需要更多对照研究,包括随机对照研究,以更好地确定在AN患儿中使用奥氮平的治疗益处和安全性。